Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Piperacillin + sulbactam is a combination antibiotic consisting of piperacillin, a broad-spectrum ureidopenicillin beta-lactam antibiotic, and sulbactam, a beta-lactamase inhibitor. Piperacillin acts by binding to penicillin-binding proteins (PBPs) in bacterial cell walls, inhibiting the final stage of peptidoglycan synthesis and leading to cell lysis. Sulbactam inhibits certain beta-lactamases produced by bacteria that would otherwise degrade piperacillin, thereby extending its antibacterial spectrum to include organisms that produce these enzymes. This combination is primarily used for the treatment of moderate-to-severe infections caused by susceptible Gram-positive and Gram-negative bacteria, including those resistant to other penicillins due to beta-lactamase production.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Piperacillin + sulbactam.